Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $12.9952W HIGH $19.10
Volume
3.51 M
Value Traded
73.10 M
Short % Float
0.13%
+3.7%Week
+1.7%1 Month
+11.84%3 Month
+2.43%6 Month
-6.88%5 Year
-40.59%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
59.34 B
EPS (TTM)
0.41
P/E Ratio
44.89
Ent. Value
77.88 B
Total Shares
3.20 B
Float Shares
3.18 B
Insiders
0.00%
Institutions
3.28%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
TAK Catalyst Timeline
Dated clinical, regulatory and corporate events for Takeda Pharmaceutical Company Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for Takeda Pharmaceutical Company Limited
148Total events
36Upcoming
75Tier-1 (high impact)
2022 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationZasocitinibFiledPresentation
Zasocitinib Phase 3 LATITUDE data presented in late-breaking and oral sessions at EADV Congress 2026
moderate-to-severe plaque psoriasissource ↗
▲Topline ReadoutZasocitinibFiledClinical Data
New Phase 3 LATITUDE head-to-head results of zasocitinib vs deucravacitinib announced
moderate-to-severe plaque psoriasissource ↗
▲FDA Filing AcceptedZasocitinibFiledRegulatory Filing
FDA accepts NDA under Priority Review for zasocitinib in moderate-to-severe plaque psoriasis
moderate-to-severe plaque psoriasissource ↗
▲EU MAA SubmissionZasocitinibFiledEx-US Regulatory
EMA accepts MAA for zasocitinib in moderate-to-severe plaque psoriasis
moderate-to-severe plaque psoriasissource ↗
▲Priority ReviewZasocitinibFiledRegulatory Filing
FDA grants Priority Review for zasocitinib NDA in plaque psoriasis
moderate-to-severe plaque psoriasissource ↗
▲PublicationOveporextonApprovedPresentation
NEJM publishes results from two Phase 3 studies of oveporexton in NT1
narcolepsy type 1source ↗
▲Oral PresentationZasocitinibFiledPresentation
Zasocitinib Phase 3 LATITUDE data presented in late-breaking and oral sessions at EADV 2026
moderate-to-severe plaque psoriasissource ↗
▲Topline ReadoutZasocitinibFiledClinical Data
Phase 3 LATITUDE head-to-head results of zasocitinib vs deucravacitinib presented
moderate-to-severe plaque psoriasissource ↗
▲FDA ApprovalRusfertideApprovedFDA Decision
FDA approval of MIMRYLO for erythrocytosis in adults with polycythemia vera
polycythemia verasource ↗
▲Primary Endpoint MetRusfertideApprovedClinical Data
VERIFY met all efficacy endpoints
polycythemia verasource ↗
▲Primary Endpoint MetRusfertideApprovedClinical Data
VERIFY met all efficacy endpoints including primary endpoint of clinical response during Weeks 20-32
polycythemia verasource ↗
●Trial CompletionRusfertideApprovedTrial
All patients completed randomized placebo-controlled portion of VERIFY
polycythemia verasource ↗
●OLE InitiatedRusfertideApprovedTrial
Open-label extension of VERIFY ongoing
polycythemia verasource ↗
▲FDA ApprovalORZEYFULApprovedFDA Decision
Japan MHLW approves ORZEYFUL (oveporexton) for narcolepsy type 1 in adults
narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adultssource ↗
▲FDA ApprovalORZEYFULApprovedFDA Decision
FDA approved ORZEYFUL (oveporexton) for narcolepsy type 1 in adults
narcolepsy type 1source ↗
▲FDA ApprovalORZEYFULApprovedFDA Decision
First approval of ORZEYFUL (oveporexton) in China
narcolepsy type 1source ↗
●NDA SubmissionORZEYFULApprovedRegulatory Filing
ORZEYFUL NDA under review in US and Japan
narcolepsy type 1source ↗
▲Priority ReviewRusfertideApprovedRegulatory Filing
Rusfertide granted FDA Priority Review
polycythemia verasource ↗
▲Topline ReadoutZasocitinibFiledClinical Data
Zasocitinib positive topline results in head-to-head Phase 3 trial vs deucravacitinib
psoriasissource ↗
◆Oral PresentationZasocitinibFiledPresentation
Secondary endpoint data from Phase 3 psoriasis studies presented at AAD Innovation Academy
moderate-to-severe plaque psoriasissource ↗
▲Partnership / LicenseCorporate
Landmark collaboration with Indonesian Government to strengthen plasma ecosystem and expand access to PDMPs
◆PDUFA DateOveporextonApprovedRegulatory Filing
PDUFA goal date set for Q3 2026
narcolepsy type 1source ↗
◆PDUFA DateRusfertideApprovedRegulatory Filing
PDUFA goal date set for Q3 2026
polycythemia verasource ↗
●Trial CompletionZasocitinibFiledTrial
Head-to-head Phase III trial vs Sotyktu expected to complete in July 2026
moderate to severe plaque psoriasissource ↗
▲Oral PresentationORZEYFULApprovedPresentation
Phase 3 results presented at SLEEP 2026
narcolepsy type 1source ↗
◆Management ChangeCorporate
Appointment of Julie Kim as Representative Director, President and CEO
▲Full ResultsOveporextonApprovedClinical Data
Pivotal study data show Oveporexton improved daily function, cognition and nighttime sleep
Narcolepsy Type 1source ↗
▲Topline ReadoutZasocitinibFiledClinical Data
Zasocitinib significantly outperforms deucravacitinib in head-to-head Phase 3 psoriasis study
psoriasissource ↗
●sBLA SubmissionENTYVIOApprovedRegulatory Filing
U.S. FDA accepts supplemental Biologics License Application for intravenous ENTYVIO in pediatric UC and CD
pediatric ulcerative colitis and Crohn's diseasesource ↗
◆Timing GuidanceicotrokinraFiledPresentation
PDUFA decision expected for icotrokinra
plaque psoriasissource ↗
▲Oral PresentationORZEYFULApprovedPresentation
ORZEYFUL Phase 3 results presented at SLEEP 2026
narcolepsy type 1source ↗
▼Restructuring LayoffsCorporate
Takeda announces layoff of about 4,500 employees in fiscal year 2026 as part of transformation program
▲Primary Endpoint MetTAK-881FiledClinical Data
TAK-881在二/三期臨床試驗中達到主要終點，PK表現與HYQVIA相當
原發性免疫缺陷病（PID）source ↗
▲Secondary Endpoint DataTAK-881FiledClinical Data
TAK-881-3001: profils de sécurité, efficacité et tolérance comparables à HYQVIA
déficit immunitaire primaire (DIP)source ↗
▲Primary Endpoint MetTAK-881FiledClinical Data
TAK-881-3001 met primary endpoint demonstrating PK comparability to HYQVIA
Primary Immunodeficiency Disease (PID)source ↗
▲Topline ReadoutTAK-881FiledClinical Data
Positive topline results from TAK-881-3001
Primary Immunodeficiency Disease (PID)source ↗
●Timing GuidanceZasocitinibFiledPresentation
NDA submission expected at start of fiscal year 2026 (April 2026)
moderate to severe plaque psoriasissource ↗
◆Timing GuidanceRusfertideApprovedPresentation
Protagonist opt-out decision expected within 90 days after 120-day period
polycythemia verasource ↗
▲Late-BreakerZasocitinibFiledPresentation
Late-breaking abstract presentation at AAD 2026
moderate-to-severe plaque psoriasissource ↗
●Oral PresentationZasocitinibFiledPresentation
Investor conference call to discuss Phase 3 data
moderate-to-severe plaque psoriasissource ↗
▲FDA Filing AcceptedRusfertideApprovedRegulatory Filing
FDA accepted NDA for rusfertide
polycythemia verasource ↗
▲Priority ReviewRusfertideApprovedRegulatory Filing
FDA granted Priority Review for rusfertide NDA
polycythemia verasource ↗
▲Priority ReviewOveporextonApprovedRegulatory Filing
FDA granted Priority Review for oveporexton NDA
narcolepsy type 1source ↗
▲FDA Filing AcceptedOveporextonApprovedRegulatory Filing
FDA accepted NDA and granted priority review for oveporexton
narcolepsy type 1source ↗
▲Product LaunchFRUZAQLAApprovedPost-Market
FRUZAQLA now reimbursed in Ontario via Exceptional Access Program
metastatic colorectal cancersource ↗
●Quarterly UpdateCorporate
Takeda reports FY2025 Q3 earnings for nine months ended December 31, 2025
Past FDA Catalysts and PDUFA Decisions
How TAK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-28 | Mimrylo (rusfertide acetate) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B77 / 100
Pipeline Score
$45.6B
Pipeline Value
$126.9B
Commercial Value
Undervalued
Valuation Signal
87
Drugs Scored
2.6x
rNPV / MCap
Top 3%
Large Pharma(rank 21 of 658)
Percentile Rank
Takeda Pharmaceutical Company Limited holds a solid B-grade pipeline (77/100), with $45.7B risk-adjusted pipeline value, led by SYR-472 in Type 2 Diabetes Mellitus (Phase 3).
Commercial products (revenue basis: latest annual revenue in its 20-F, converted from JPY to USD, to Mar 2026; product lines from the latest annual filing) Revenue $29.9B x 4.2 = $126.9B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| ENTYVIO | $6.4B | $6.1B | +4.8% |
| TAKHZYRO | $1.5B | $1.5B | +0.3% |
| VYVANSE/ELVANSE | $1.3B | $2.3B | -42% |
| GATTEX/REVESTIVE | $968M | $972M | -0.4% |
| TAKECAB/VOCINTI | $954M | $869M | +9.9% |
| Albumin | $932M | $939M | -0.8% |
| ADCETRIS | $931M | $857M | +8.7% |
| TRINTELLIX | $809M | $835M | -3.1% |
| LEUPLIN/ENANTONE | $802M | $792M | +1.3% |
| ADVATE | $701M | $742M | -5.6% |
| ELAPRASE | $667M | $646M | +3.3% |
| NINLARO | $545M | $606M | -10% |
Top 12 of 29 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SYR-472 Small moleculeCompletedNCT02324569 | Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 240 | Dec 28, 2016 |
Clinical Trial Results
Readouts, endpoints and source filings for every TAK program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TAK-881 | primary immunodeficiency disease | Phase 2/3 | 2026-05-06 | comparable pharmacokinetics between TAK-881 and HYQVIARead More | Riassunto: Takeda annuncia i risultati principali positivi dallo studio clinico pivotale di fase 2/3 su TAK-881 nella malattia da immunodeficienza primaria (IDP)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Duprey Lauren RusckowskiOfficer (Chief Transformation Officer) | Sell | -34,535 191,522 held | $18.54 | 09/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TAK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PFM HEALTH SCIENCES, LP | 0.6 % | 7.12 M | 444.17 K |
TAK Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TAK ranks across every disease it competes in
Competitive Position is a premium feature
See how TAK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTAK News
TAKZasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
Takeda announced promising results from three Phase 3 studies of zasocitinib, a next-generation TYK2 inhibitor for moderate-to-severe plaque psoriasis. The data, presented at the EADV Congress 2026, indicates that zasocitinib outperforms Deucravacitinib in efficacy. This oral medication offers a convenient once-daily dosing regimen, enhancing treatment adherence.
Read more →TAKTakeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
Takeda has announced that it will present new data from its oncology pipeline at the ESMO Congress in Madrid from October 23-27, 2026. The highlights include a late-breaking abstract on TAK-921 and presentations on TAK-928. This showcases Takeda's commitment to advancing cancer treatment options.
Read more →TAKTakeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
Takeda has announced a commitment of USD 22.2 million to four new Global Corporate Social Responsibility partners. This initiative aims to enhance climate-resilient health systems in low- and middle-income countries. The funding aligns with Takeda's mission to promote better health and a brighter future globally.
Read more →TAKU.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
Takeda announced that the FDA has accepted its New Drug Application for zasocitinib, a next-generation oral TYK2 inhibitor, under Priority Review. This drug targets adults with moderate-to-severe plaque psoriasis and has shown rapid and durable skin clearance in Phase 3 trials. The acceptance marks a significant step in the potential treatment landscape for psoriasis.
Read more →TAKNew England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
Takeda announced the publication of results from two Phase 3 studies in the New England Journal of Medicine, demonstrating that oveporexton (ORZEYFUL) significantly improves symptoms and quality of life for patients with narcolepsy type 1. This drug is noted for being the first and only treatment addressing the underlying cause of the condition.
Read more →TAKTakeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
Takeda has received FDA approval for MIMRYLO (rusfertide), a new treatment for erythrocytosis in adults with polycythemia vera. This first-in-class hepcidin mimetic aims to regulate iron distribution and control red blood cell overproduction. The approval represents a potential shift in the treatment paradigm for this blood cancer.
Read more →TAKORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Takeda's ORZEYFUL (oveporexton) has been approved in Japan as the first and only medication to treat narcolepsy type 1. This innovative oral orexin receptor 2 agonist addresses the underlying cause of the condition, rather than just alleviating symptoms. The approval marks a significant advancement in narcolepsy treatment options.
Read more →TAKU.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Takeda has received FDA approval for ORZEYFUL (oveporexton), the first oral treatment specifically targeting narcolepsy type 1. This approval is significant as it addresses the underlying orexin deficiency that causes the disorder. ORZEYFUL is expected to improve the quality of life for patients suffering from this chronic condition.
Read more →TAKTakeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
Takeda has reported its financial results for the first quarter of FY2026, highlighting strong operational momentum and disciplined execution. The company is advancing its commercial launch preparations while achieving significant milestones in its R&D pipeline. This performance reflects Takeda's commitment to its long-term strategy.
Read more →TAKTakeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
Takeda has released promising data from two Phase 3 studies of zasocitinib, a selective TYK2 inhibitor, for treating moderate-to-severe plaque psoriasis. The results indicate that the drug achieved high rates of skin clearance across various body areas, including challenging sites. This data was presented at the 2026 AAD Innovation Academy.
Read more →TAKTakeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
Takeda has partnered with the Indonesian Government to enhance the country's plasma ecosystem. This collaboration focuses on increasing access to plasma-derived medicinal products, benefiting both Indonesia and the global community. The initiative involves key ministries, indicating strong governmental support for healthcare improvements.
Read more →TAKTakeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
Takeda has announced new assignments of directors, including the appointment of Julie Kim as the Representative Director, President, and CEO. This leadership change is part of the company's ongoing strategy to enhance its governance and operational effectiveness. The announcement reflects Takeda's commitment to strong leadership in the biopharma sector.
Read more →TAKNew Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
Takeda's new pivotal study data reveals that Oveporexton significantly enhances daily function, cognition, and nighttime sleep quality in individuals with Narcolepsy Type 1. These findings suggest a promising advancement in treatment options for this condition, potentially improving the quality of life for affected patients.
Read more →TAKTakeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
Takeda's Zasocitinib has demonstrated significant efficacy in a Phase 3 study, outperforming Deucravacitinib in treating psoriasis. This promising result may redefine expectations for oral treatments in this indication. The findings suggest that Zasocitinib could become a leading option for patients seeking effective psoriasis management.
Read more →TAKU.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
Takeda's application for intravenous ENTYVIO® (vedolizumab) has been accepted by the U.S. FDA for the treatment of pediatric patients with ulcerative colitis and Crohn's disease. This acceptance marks a crucial step in expanding treatment options for children suffering from these conditions. ENTYVIO® is already approved for adult patients, and this development could enhance its accessibility to younger patients.
Read more →TAKNet Debt and Adjusted Net Debt Takeda defines Net Debt as the book value of bonds and loans on consolidated statements of financial position adjusted only for cash and cash equivalents and Adjusted Net Debt first by calc
Takeda has released detailed explanations of its financial measures, particularly focusing on Non-IFRS metrics, such as Core Revenue and Adjusted Free Cash Flow. These measures aim to provide clarity on the company's operations by excluding non-recurring items and those unrelated to its core performance. However, the complexity and new terminology introduced may challenge investors' understanding and impede cross-comparisons with other firms in the industry. The company emphasizes the use of these metrics for internal evaluation and planning while cautioning that they should not be viewed in isolation from standard IFRS measures.
Read more →TAKTakeda cuts send layoffs soaring in May, rising year over year
Takeda has announced significant layoffs, cutting approximately 4,500 employees as part of a cost-cutting transformation program. This decision contributes to a record number of layoffs in the biopharma sector for May 2026, with a year-over-year increase in job cuts. Despite the layoffs, Takeda is also hiring for new roles to support future growth.
Read more →TAKFINANCIAL APPENDIX Definition of Non-IFRS Measures Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A- 1 Reconciliations and Other Financial Information FY2025 Reported Results wit
The article provides a detailed account of Takeda's non-IFRS financial measures, including definitions, reconciliations, and adjustments for financial reporting. It emphasizes the importance of Core Financial Measures, such as Core Revenue and Core Operating Profit, and their role in evaluating the company's underlying business performance. Additionally, the article discusses how Constant Exchange Rate (CER) adjustments provide insight into financial results unaffected by currency fluctuations. Overall, it serves as a comprehensive guide for understanding Takeda's financial strategy and reporting metrics for FY2025.
Read more →TAKTakeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
Takeda has announced its full year results for FY2025 and provided an outlook for FY2026. The report highlights progress in its pipeline, although specific details about the results and outlook are not included in the provided text.
Read more →TAKIncreased capital boosts biotech R&D job postings, employment
The biotech R&D job market is experiencing significant growth, with job postings increasing by 21% year-over-year as of April. Employment in the sector reached a record high in Q1, driven by an improving capital environment and increased follow-on offerings. Major companies are actively hiring, indicating a positive trend for biotech professionals seeking opportunities.
Read more →About Takeda Pharmaceutical Company Limited
BIOPHARMAWATCH ELITE PLUS
Trade the next TAK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime